Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Home visit with encouragement to receive influenza vaccination compared to home visit with safety intervention · people aged 60 years and older living in the community
Enhancing vaccination access showed no clear difference in home visit with encouragement to receive influenza vaccination… compared with no intervention or another intervention (high certainty).
1 finding from 1 review
Home visit by nurse or group sessions with encouragement to receive influenza vaccination plus care plan developed with physician compared to no intervention · people aged 60 years and older living in the community
1 finding from 1 review
Posters in clinic displaying influenza vaccination rates to encourage doctors to compete plus postcards to participants compared to no intervention · people aged 60 years and older living in the community
Provider‐ or system‐based interventions leads to higher posters in clinic displaying influenza vaccination rates to… compared with no intervention or another intervention (high certainty).
1 finding from 1 review
Posters in clinic displaying influenza vaccination rates to encourage doctors to compete plus postcards to participants compared to posters alone · people aged 60 years and older living in the community
Provider‐ or system‐based interventions showed no clear difference in posters in clinic displaying influenza vaccination rates to… compared with no intervention or another intervention (high certainty).
1 finding from 1 review
Facilitator encouragement of prevention manoeuvres including influenza vaccination compared to no intervention · people aged 60 years and older living in the community
1 finding from 1 review
CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Intervention not reported
Influenza · People aged 60 or older living in long‐term care institutions
1 finding from 1 review
Intervention not reported
Lower respiratory tract infection · People aged 60 or older living in long‐term care institutions
1 finding from 1 review
Intervention not reported
Admission to hospital for respiratory illness · People aged 60 or older living in long‐term care institutions
1 finding from 1 review
Intervention not reported
Deaths from influenza or its complications · People aged 60 or older living in long‐term care institutions
1 finding from 1 review
Intervention not reported
Deaths from all causes · People aged 60 or older living in long‐term care institutions
1 finding from 1 review
Cumulative incidence of herpes zoster, 3.1 years · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to lower cumulative incidence of herpes zoster, 3.1 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects of any severity (systemic symptoms) · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any systemic symptomClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts ‐ did not receive second dose Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher dropouts ‐ did not receive second doseClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review